Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration
Immunotherapy Advances · 01.01.2023 · 3 (1)
DOI: 10.1093/immadv/ltad012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunotherapy Advances, online erschienen am 18.07.2023. Verfasst von María José Mansilla und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, LCMN, Germans Trias i Pujol University Hospital and Research Institute, Campus Can Ruti, Badalona, Spain. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union’s Horizon 2020, ISCIII-Subdirección General de Evaluación, Fondo Europeo de Desarrollo Regional.
Abstract (Originalsprache)
Tolerogenic dendritic cells (tolDCs) are a promising strategy to treat autoimmune diseases since they have the potential to re-educate and modulate pathological immune responses in an antigen-specific manner and, therefore, have minimal adverse effects on the immune system compared to conventional immunosuppressive treatments. TolDC therapy has demonstrated safety and efficacy in different experimental models of autoimmune disease, such as multiple sclerosis (MS), type 1 diabetes (T1D), and rheumatoid arthritis (RA). Moreover, data from phase I clinical trials have shown that therapy with tolDCs is safe and well tolerated by MS, T1D, and RA patients. Nevertheless, various parameters need to be optimized to increase tolDC efficacy. In this regard, one important parameter to be determined is the most appropriate route of administration. Several delivery routes, such as intravenous, subcutaneous, intraperitoneal, intradermal, intranodal, and intraarticular routes, have been used in experimental models as well as in phase I clinical trials. This review summarizes data obtained from preclinical and clinical studies of tolDC therapy in the treatment of MS, T1D, and RA and their animal models, as well as data from the context of cancer immunotherapy using mature peptide-loaded DC, and data from in vivo cell tracking experiments, to define the most appropriate route of tolDC administration in relation to the most feasible, safest, and effective therapeutic use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Immunology, LCMN, Germans Trias i Pujol University Hospital and Research Institute, Campus Can Ruti, Badalona, Spain.
- Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain.
- Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
ORCID-Profile: Eva M Martínez-Cáceres
Förderung
- European Union’s Horizon 2020
- ISCIII-Subdirección General de Evaluación
- Fondo Europeo de Desarrollo Regional
- Government of Catalonia
Zitieren
APA
Mansilla, M. J., Hilkens, C. M. U., & Martínez-Cáceres, E. M. (2023). Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration. Immunotherapy Advances, 3(1). https://doi.org/10.1093/immadv/ltad012
Vancouver
Mansilla MJ, Hilkens CMU, Martínez-Cáceres EM. Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration. Immunotherapy Advances. 2023;3(1). doi:10.1093/immadv/ltad012
BibTeX
@article{Mansilla2023,
author = {Mansilla, María José and Hilkens, Catharien M U and Martínez-Cáceres, Eva M},
title = {Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration},
journal = {Immunotherapy Advances},
year = {2023},
volume = {3},
number = {1},
doi = {10.1093/immadv/ltad012}
}
EUVIMED